摘要
目的 观察含吉西他滨联合化疗方案治疗难治或复发非霍奇金淋巴瘤的疗效。方法 将76例非霍奇金淋巴瘤患者根据治疗过程中是否应用吉西他滨分为对照组（非吉西他滨组）和观察组（吉西他滨组）各38例。对比两组临床疗效及不良反应。并比较B细胞与T细胞型难治复发非霍奇金淋巴瘤患者应用吉西他滨方案的疗效差异。结果两组ORR及CR比较,差异无统计学意义（P〉0.05）。观察组PR显著优于对照组,差异具有统计学意义（P〈0.05）。两组年龄〉60岁患者ORR、CR及PR比较,差异无统计学意义（P〉0.05）。观察组B细胞型患者ORR为42.86%,与T细胞型患者ORR 35.29%比较,差异无统计学意义（P〉0.05）。观察组Ⅲ~Ⅳ级不良反应中骨髓抑制与对照组比较,差异无统计学意义（P〉0.05）;观察组Ⅲ~Ⅳ级不良反应中胃肠道反应发生率与对照组比较,差异有统计学意义（P〈0.05）。结论 难治或复发NHL患者应用含吉西他滨方案联合化疗,PR率优于不含吉西他滨方案,并且Ⅲ~Ⅳ级胃肠道反应发生率低。T细胞型患者应用含吉西他滨方案化疗可得到与B细胞型相当疗效。
Objective To observe the efficacy of gemcitabine combined with chemotherapy in the treatment of refractory or relapsed non-Hodgkin~ lymphoma（ NHL ）. Methods 76 patients with non- Hodgking lymphoma were divided into the control group （gemcitabine group） and the observation group （gemcitabine group）, each with 38 patients. Clinical efficacy and adverse re- actions of the 2 groups were compared. The efficacy of gemcitabine in patients with B cells and T cells refractory and relapsed non- Hodgkin＇s lymphoma were compared. Results There was no significant difference between the 2 groups （ ORR and CR） （ P 〉 0.05）. The PR of the observation group was significantly better than the control group, the difference was statistically significant （ P 〈 0.05 ）. There was no significant difference in ORR, CR and PR of patients over 60 between the 2 groups （ P 〉 0.05 ）. In the observation group, ORR of B cell type was 42.86%, ORR of T cell type was 35.29%, the difference was not statistically significant（ P 〉0.05 ）. The difference of Ⅱ-Ⅳ myelosuppression between the 2 groups was not statistically significant（ P 〉 0.05 ） ; There were significant differences in the Ⅲ - Ⅳ gastrointestinal adverse reaction between the 2 groups （P 〈 0.05 ）. Conclusion The patients with refractory or relapsed NHL treated with gemcitabine combined with chemotherapy,the rate of PR is superior to that without gemcitabine, and a low incidence of grade Ill/IV gastrointestinal reactions. T cell type patients with gemcitabine chemotherapy can be obtained with the B cell type equivalent efficacy.
出处
《实用癌症杂志》
2016年第12期2073-2075,共3页
The Practical Journal of Cancer
关键词
难治或复发非霍奇金淋巴瘤
吉西他滨
化疗
Relapsed or refractory non-hodgkin
lymphoma（ NHL ）
Gemcitabine
Chemotherapy
